Advertisement
Research Article

Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures

  • Aaron S. Kesselheim mail,

    akesselheim@partners.org

    Affiliation: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Bo Wang,

    Affiliation: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • David M. Studdert,

    Affiliation: Schools of Law and Population Health, University of Melbourne, Melbourne, Australia

    X
  • Jerry Avorn

    Affiliation: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Published: August 07, 2012
  • DOI: 10.1371/journal.pmed.1001280

Reader Comments (1)

Post a new comment on this article

Dramatic lack of external validity

Posted by AdamJacobs on 17 Aug 2012 at 16:55 GMT

This has to be one of the least surprising results I've ever seen.

You select a group of authors specifically on the grounds that they were alleged to have been part of some kind of wrongdoing. You then find that they don't completely play by the rules.

I'm really not sure what kind of message we're supposed to take away from that that wasn't completely obvious from the start.

Competing interests declared: Most of my clients are pharmaceutical companies